Article Sidebar

Submitted
July 30, 2025
Accepted
January 5, 2026
Published
December 31, 2025
Download
PDF
Statistic
Read Counter : 52

Main Article Content

Abstract

This molecular study investigates the expression of the long non-coding RNA (lncRNA) MALAT1 in tissue samples from patients with oral squamous cell carcinoma (OSCC). Quantitative PCR was used to assess MALAT1 levels in 40 OSCC samples and 20 adjacent normal tissues. High MALAT1 expression was significantly correlated with increased tumor size, lymph node metastasis, and poor 3-year survival outcomes. These results highlight MALAT1 as a potential biomarker for OSCC progression and a possible target for therapeutic intervention. Functional studies are warranted to explore its role in epithelial-mesenchymal transition and invasion. 

Keywords

Oral cancer lncRNA MALAT1 tumor markers prognosis

Article Details

License

Copyright (c) 2025 Shaimaa Obaid Hasson, Asmaa Sami Jawad, Dina M.R.Al-khafaf, Zaman S. Hamza, Heba F. Altamimi (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Shaimaa Obaid Hasson (2025) “Expression of lncRNA MALAT1 in Oral Squamous Cell Carcinoma: Correlation with Tumor Invasiveness and Prognosis”, Future Dental Research, 3(2), pp. 7–20. doi:10.57238/fdr.2024.152576.1015.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

How to Cite

Shaimaa Obaid Hasson (2025) “Expression of lncRNA MALAT1 in Oral Squamous Cell Carcinoma: Correlation with Tumor Invasiveness and Prognosis”, Future Dental Research, 3(2), pp. 7–20. doi:10.57238/fdr.2024.152576.1015.

References

  1. Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer - systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35:747-55. doi: 10.1002/hed.22015.
  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209-49. doi: 10.3322/caac.21660.
  3. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861-74. doi: 10.1038/nrg3074.
  4. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38. doi: 10.1186/1476-4598-10-38.
  5. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19(3):143-57. doi: 10.1038/nrm.2017.104.
  6. Ji P, Diederichs S, Wang W. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non–small cell lung cancer. Oncogene. 2003;22(39):8031-41. doi: 10.1038/sj.onc.120692.
  7. Hirata H, Hinoda Y, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res. 2015;75(7):1322-31. doi: 10.1158/0008-5472.CAN-14-2931.
  8. Wang J, Zhou Y, Lu J, Sun Y, Xiao W, Tong X. The lncRNA MALAT1 promotes cell proliferation and migration in oral squamous cell carcinoma by regulating the miR-125b/STAT3 axis. Cancer Cell Int. 2020;20:240. doi: 10.1186/s12935-020-01309-0.
  9. Dong Y, Liang G, Yuan B, Yang C, Gao R, Zhou X. MALAT1 promotes the invasion and metastasis of oral squamous cell carcinoma by sponging miR-101 and upregulating EZH2 expression. Oncotarget. 2017;8(55):91521-33. doi: 10.18632/oncotarget.21392.
  10. Lin J, Zhan Y, Zhang Z, Sun L, Zhang Q. LncRNA MALAT1 modulates cell proliferation and invasion through regulating miR-124/Slug pathway in OSCC. Biosci Rep. 2020;40(5):BSR20193325. doi: 10.1042/BSR20193325.
  11. Gutschner T, Hammerle M, Diederichs S. MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med (Berl). 2013;91(7):791-801. doi: 10.1007/s00109-013-1028-y.
  12. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47-62. doi: 10.1038/nrg.2015.10.
  13. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298-307. doi: 10.1016/j.cell.2013.02.012.
  14. Zhang B, Wang Q, Pan X. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol. 2007;210(2):279-89. doi: 10.1002/jcp.20869.
  15. Liu Y, Zhao J, Zhang W, et al. LncRNA MALAT1 promotes androgen-independent prostate cancer cell proliferation by regulating androgen receptor signaling. Onco Targets Ther. 2017;10:5215-23. doi: 10.2147/OTT.S146927.
  16. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-74. doi: 10.1146/annurev.immunol.23.021704.115526.
  17. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783-801. doi: 10.1016/j.cell.2006.02.015.
  18. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4-5):309-16. doi: 10.1016/j.oraloncology.2008.06.002.
  19. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703-19. doi: 10.4161/rna.20481.
  20. Chen J, Liu A, Wang Z, Wang B, Chai X. LncRNA MALAT1 promotes epithelial-to-mesenchymal transition and metastasis of breast cancer via alternative splicing regulation. Mol Cancer. 2018;17(1):1-14. doi: 10.1186/s12943-018-0781-1.
  21. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. Long non-coding RNA MALAT1 contributes to hepatocellular carcinoma proliferation by acting as a sponge for miR-204. Mol Cancer. 2014;13:112. doi: 10.1186/1476-4598-13-112.
  22. Qiang R, He G, Wang W, Xu D, Qin P, Li J. LncRNA MALAT1 promotes tumorigenesis and predicts poor prognosis in oral squamous cell carcinoma. Tumour Biol. 2016;37(12):12023-12030. doi: 10.1007/s13277-016-5092-4.
  23. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT1 promotes the proliferation and metastasis of OSCC cells through the miR-124/C-MYC pathway. J Cell Biochem. 2019;120(4):6361-6370. doi: 10.1002/jcb.27890.
  24. Zhang J, Lin Z, Gao Y, Li Y, Zhang X. LncRNA MALAT1 facilitates tumor growth and metastasis in oral squamous cell carcinoma via miR-143-3p/ELK1 axis. J Cell Mol Med. 2020;24(2):1398-1411. doi: 10.1111/jcmm.14833.
  25. Sun Y, Ma L, Yan F. LncRNA MALAT1 contributes to proliferation and metastasis in oral squamous cell carcinoma. Oral Dis. 2019;25(5):1116-1123. doi: 10.1111/odi.13065.
  26. Clemson CM, Hutchinson JN, Sara SA. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell. 2009;33(6):717-726. doi: 10.1016/j.molcel.2009.01.026.
  27. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925-938. doi: 10.1016/j.molcel.2010.08.011.
  28. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non–small cell lung cancer. Oncogene. 2003;22(39):8031-8041. doi: 10.1038/sj.onc.1206928.
  29. Gutschner T, Hämmerle M, Diederichs S. MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med. 2013;91(7):791-801. doi: 10.1007/s00109-013-1028-y.
  30. Yang L, Lin C, Liu W, Zhang J. Role of MALAT1 in oral cancer progression via EMT signaling pathway. J Oral Pathol Med. 2020;49(3):222-230. doi: 10.1111/jop.12977.
  31. Zhang X, Hamblin MH, Yin KJ. The long noncoding RNA Malat1: its physiological and pathophysiological functions. RNA Biol. 2017;14(12):1705-1714. doi: 10.1080/15476286.2017.1358347.
  32. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38. doi: 10.1186/1476-4598-10-38.
  33. Li X, Wu Z, Fu X, Han W. LncRNAs: insights into their function and mechanics in underlying disorders. Mutat Res. 2014;762:1-21. doi: 10.1016/j.mrrev.2014.09.001.
  34. Lu L, Sun K, Chen X. Genome-wide assessment of long noncoding RNAs in non-small cell lung cancer. Oncotarget. 2017;8(62):104831-104843. doi: 10.18632/oncotarget.22117.
  35. Xie H, Ma H, Zhou D. LncRNA UCA1 promotes proliferation and invasion of bladder cancer cells through targeting miR-145. BMC Cancer. 2015;15:893. doi: 10.1186/s12885-015-1882-9.
  36. Peng W, Si S, Zhang Q. Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by regulating sphingosine kinase 1 expression. Oncol Rep. 2017;38(6):3717-3724. doi: 10.3892/or.2017.6019.
  37. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, et al. Epigenetic silencing of the tumour suppressor gene p15 by its antisense RNA. Nature. 2008;451(7175):202-206. doi: 10.1038/nature06468.
  38. Zhang Y, He R, Zhan Y, et al. MALAT1 promotes OSCC progression by regulating E-cadherin through β-catenin. J Oral Pathol Med. 2020;49(4):316-325. doi: 10.1111/jop.12995.
  39. Liu L, Zhai Y, Zhu Y. LncRNA MALAT1 as a biomarker for OSCC prognosis. Mol Cell Biochem. 2020;474(1-2):11-19. doi: 10.1007/s11010-020-03801-6.
  40. Hu L, Wu Y, Tan D, Meng H, Wang K, Bai Y, et al. Upregulation of long non-coding RNA MALAT1 contributes to proliferation and metastasis in oral squamous cell carcinoma. Tumour Biol. 2016;37(2):2165-2172. doi: 10.1007/s13277-015-3991-5.
  41. Guo F, Li Y, Liu Y. Long non-coding RNA MALAT1 regulates epithelial-mesenchymal transition via the PI3K/AKT signaling pathway in OSCC. Int J Clin Exp Pathol. 2019;12(5):1563-1572.
  42. He B, Bai Y, Kang W. NF-κB and β-catenin pathways as key mediators in MALAT1-induced OSCC invasion. Cancer Gene Ther. 2021;28(4):299-311. doi: 10.1038/s41417-020-00235-9.
  43. Zhao J, Zhang X, Zhou Y. Down-regulation of MMP-9 by siRNA inhibits invasion and migration of human tongue carcinoma cells. Oral Oncol. 2011;47(6):564-569. doi: 10.1016/j.oraloncology.2011.04.009.
  44. Zhang C, Wang H, Xu L. MALAT1 promotes EMT in OSCC through modulation of Slug and vimentin expression. BMC Cancer. 2018;18:60. doi: 10.1186/s12885-017-3968-0.
  45. Liu T, Zhang X, Gao S. MALAT1 modulates angiogenesis and MMP-9 expression in oral cancer. Oncol Lett. 2021;21(2):158. doi: 10.3892/ol.2021.12458.
  46. Han Y, Liu Y, Gui Y, Cai Z. Long intergenic non-coding RNA MALAT1 predicts poor prognosis and promotes tumor metastasis in OSCC. Oral Oncol. 2015;51(8):751-757. doi: 10.1016/j.oraloncology.2015.05.006.
  47. Xu S, Kong D, Chen Q, Ping Y, Pang D. Oncogenic long noncoding RNA landscape in breast cancer. Mol Cancer. 2017;16(1):129. doi: 10.1186/s12943-017-0696-9.
  48. Lin C, Yang L. Long noncoding RNA in cancer: wiring signaling circuitry. Trends Cell Biol. 2018;28(4):287-301. doi: 10.1016/j.tcb.2017.11.008.
  49. Ma K, Song X, Yan F, et al. Knockdown of MALAT1 suppresses tumor growth and metastasis in OSCC via MMP regulation. BMC Oral Health. 2020;20(1):235. doi: 10.1186/s12903-020-01229-9.
  50. Zhou X, Liu S, Cai G, Kong L, Zhang T, Ren Y, et al. Long non-coding RNA MALAT1 promotes tumor growth and metastasis by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. Sci Rep. 2015;5:15972. doi: 10.1038/srep15972.
  51. Xu E, Liang X, Ji Z, Zhao S, Li L, Lang J. Blocking long noncoding RNA MALAT1 restrained the development of laryngeal and hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2019;277(2):611–21. doi:10.1007/s00405-019-05732-X.
  52. Han X, Xu Z, Tian G, Tang Z, Gao J, Wei Y, Xu X. Suppression of the long non-coding RNA MALAT-1 impairs the growth and migration of human tongue squamous cell carcinoma SCC4 cells. Arch Med Sci. 2019;15(4):992–1000. doi:10.5114/aoms.2018.73343.
  53. Yu L, Shao X, Huo L, Zhang T. Long non-coding RNA MALAT1 promotes cell proliferation and migration by regulating miR-143-3p and MAGEA9 in oral squamous cell carcinoma. Med Sci Monit. 2020;26:e924187. doi:10.12659/MSM.924187.
  54. Arun G, Aggarwal D, Spector DL. MALAT1 long non-coding RNA: functional implications. Noncoding RNA. 2020;6(2):22. doi:10.3390/ncrna6020022.
  55. Zong G, Feng X, Sun X, Du J, Wang G, Song T. LncRNA MALAT1 promotes cell proliferation and invasion by sponging miR-125b to modulate HMGA1 expression in laryngocarcinoma. Iran J Public Health. 2021;50(5):959–69. doi:10.18502/ijph.v50i5.611.
  56. Wei Y, Niu B. Role of MALAT1 as a prognostic factor for survival in various cancers: a systematic review and meta-analysis. Dis Markers. 2015;2015:164635. doi:10.1155/2015/164635.
  57. Jiang Q, Liu S, Hou L, Guan Y, Yang S, Luo Z. The implication of LncRNA MALAT1 in promoting chemo-resistance of laryngeal squamous cell carcinoma cells. J Clin Lab Anal. 2020;34(4):e23116. doi:10.1002/jcla.23116.
  58. Fang Z, Zhang S, Wang Y, Shen S, Wang F, Hao Y. Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma progression by regulating the miR-125b/STAT3 axis. Cell Physiol Biochem. 2019;52(1):258–72. doi:10.1159/000495164.
  59. Goyal A, Sharma N, Gupta R. Prognostic significance of long non-coding RNA MALAT1 in oral squamous cell carcinoma. J Oral Pathol Med. 2021;50(3):291–9. doi:10.1111/jop.13111.
  60. Li P, Zhang X, Wang H, Wang L, Liu T, Du L. MALAT1 promotes oral squamous cell carcinoma development via upregulating Aurora-A. Mol Cancer. 2017;16(1):52. doi:10.1186/s12943-017-0632-z.
  61. Huang C, Liu S, Wang H, Zhang Z, Yang Y, Zhou Z. Long non-coding RNA MALAT1 mediates epithelial-to-mesenchymal transition via Wnt/β-catenin signaling in OSCC. Cancer Manag Res. 2020;12:901–13. doi:10.2147/CMAR.S236406.
  62. Wu Y, Zhang L, Zhang L, Wang Y, Li H, Ren X. Clinical significance of lncRNA MALAT1 in OSCC tissues and serum. Onco Targets Ther. 2018;11:7391–9. doi:10.2147/OTT.S176005.
  63. Zhou X, Liu S, Cai G, Kong L, Zhang T, Ren Y, et al. Long non-coding RNA MALAT1 promotes tumor growth and metastasis by inducing epithelial–mesenchymal transition in oral squamous cell carcinoma. Sci Rep. 2015;5:15972.
  64. Wang R, Lu X, Yu R. Long non-coding RNA MALAT1 promotes EMT and cisplatin resistance of OSCC via PI3K/AKT/mTOR signaling pathway. Onco Targets Ther. 2020;13:4049–61.
  65. Xiao L, Wang W, Zhao J, Xu H, Li S, Yang X. Long noncoding RNA MALAT1 promotes cell proliferation and invasion by regulating the miR-101/EZH2 axis in oral squamous cell carcinoma. Mol Cancer. 2020;19:85. doi:10.1186/s12943-020-01225-x.
  66. Yu L, Shao X, Huo L, Zhang T. Long non-coding RNA MALAT1 promotes OSCC progression via regulation of the miR-143-3p/MAGEA9 axis. Biochem Biophys Res Commun. 2020.
  67. Chang SM, Hu WW. Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma development via microRNA-125b/STAT3 axis. J Cell Physiol. 2018;233(4):3384–96. doi:10.1002/jcp.2618.
  68. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT1 promotes the proliferation and metastasis of OSCC cells through the miR-124/C-MYC pathway. J Cell Biochem. 2019;120(4):6361–70. doi:10.1002/jcb.27890.
  69. Jiang X, Wu J, Wang J, Huang R. Tobacco and oral squamous cell carcinoma: a review of carcinogenic pathways. Tob Induc Dis. 2019;17:29. doi:10.18332/tid/105844.
  70. Pekarek L, Garrido-Gil MJ, Sánchez-Cendra A, et al. Emerging histological and serological biomarkers in oral squamous cell carcinoma. Oncol Rep. 2023;50(6):213. doi:10.3892/or.2023.8675.
  71. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118. doi:10.1038/s41580-020-00315-9.
  72. Lauritano D, Lucchese A, Contaldo M. Oral squamous cell carcinoma: diagnostic markers and prognostic indicators. J Biol Regul Homeost Agents. 2016;30(2):169–76.
  73. Ricciardiello F, Caraglia M, Iorio B, Abate T, Boccellino M, Colella G, et al. Aggressiveness pattern and second primary tumor risk in basaloid squamous cell carcinoma of the larynx. Oncotarget. 2017;8(56):95791–8. doi:10.18632/oncotarget.21327.
  74. Aquino G, Pannone G, Santoro A, Liguori G, Franco R, Serpico R, et al. pEGFR-Tyr845 expression as prognostic factor in OSCC. Cancer Biol Ther. 2012;13(11):967–77. doi:10.4161/cbt.20991.
  75. Wang Y, Lin Z, Sun L, Fan S, Huang Z, Zhang D, et al. Akt/Ezrin Tyr353/NF-κB pathway regulates EMT and metastasis in tongue SCC. Br J Cancer. 2014;110:695–705.
  76. Königshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis. J Clin Invest. 2009;119:772–87. doi:10.1172/JCI37257.
  77. Salt MB, Bandyopadhyay S, McCormick F. EMT rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 2014;4:186–99. doi:10.1158/2159-8290.CD-13-052.
  78. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
  79. Camisasca DR, Costa Silami MAN, Honorato J, Dias FL, Faria PAS, Lourenço SQC. OSCC clinicopathological features with and without recurrence. ORL J Otorhinolaryngol Relat Spec. 2011;73:170–6. doi:10.1159/000328340.
  80. Rogers SN, Laher S, Overend L, Lowe D. UW-QOL domain importance-rating in oral cancer surgery patients. J Craniomaxillofac Surg. 2002;30:125–32.
  81. Indira Priyadarshini K, Madankumar PD, Karthikeyan DR. Oral health-related quality of life after oral cancer treatment. Indian J Cancer. 2017;54:115. doi:10.4103/ijc.IJC_116_17.
  82. Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, et al. MALAT1 promotes aggressive renal cell carcinoma. Cancer Res. 2015;75:1322–31.
  83. Li S, Wang Q, Qiang Q, Shan H, Shi M, Chen B, et al. Sp1-mediated transcriptional regulation of MALAT1. J Cancer Res Clin Oncol. 2015;141:1909–20.
  84. Wang X, Li M, Wang Z, Han S, Tang X, Ge Y, et al. Silencing of MALAT1 by miR-101 and miR-217 in esophageal SCC. J Biol Chem. 2015;290:3925–35.
  85. Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. MALAT1 regulates metastasis phenotype of lung cancer. Cancer Res. 2013;73:1180–9.
  86. Lunardi S, Muschel RJ, Brunner TB. Stromal compartments in pancreatic cancer. Cancer Lett. 2014;343:147–55.
  87. Bourboulia D, Stetler-Stevenson WG. MMPs and TIMPs in tumor cell adhesion. Semin Cancer Biol. 2010;20:161–8.
  88. Wang F, Ren S, Chen R, Lu J, Shi X, Zhu Y, et al. MALAT-1 as diagnostic urinary biomarker for prostate cancer. Oncotarget. 2014;5:11091–102.
  89. Tang H, Wu Z, Zhang J, Su B. Salivary lncRNA as marker for OSCC. Mol Med Rep. 2013;7:761–6.
  90. Zhang J, Zhang B, Wang T, Wang H. MALAT1 overexpression as unfavorable prognostic factor: meta-analysis. Int J Clin Exp Med. 2015;8:5499–505.
  91. Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, et al. MALAT1 promotes colorectal cancer metastasis via SFPQ/PTBP2 complex. Br J Cancer. 2014;111:736–48.
  92. Shen L, Chen L, Wang Y, Jiang X, Xia H, Zhuang Z. MALAT1 promotes brain metastasis in lung cancer. J Neurooncol. 2015;121:101–8.
  93. Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding Q, et al. MALAT1 promotes gallbladder cancer metastasis via ERK/MAPK. Cancer Biol Ther. 2014;15:806–14.doi: 10.4161/cbt.28584
  94. Chen H, Xin Y, Zhou L, Huang JM, Tao L, Cheng L, Tian J. Cisplatin and paclitaxel target lncRNAs in laryngeal SCC. Med Oncol. 2014;31:246.doi: 10.1007/s12032-014-0246-7
  95. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-κB represses E-cadherin and enhances EMT. Oncogene. 2007;26:711–24.

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.